India to Taiwan: Carboplatin Export Trade Route

The India to Taiwan Carboplatin corridor is one of India's established pharmaceutical export routes, with 30 shipments documented worth a combined $1.6M USD. The route is dominated by FRESENIUS KABI ONCOLOGY LIMITED, which alone accounts for roughly 82% of all export value, reflecting the consolidated nature of India's carboplatin manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $51.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with carboplatin's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 22 days port-to-port. The route has recorded an annual growth rate of 16.6%, placing it at rank #13 among India's top carboplatin export destinations globally.

On the import side, key buyers of Indian carboplatin in Taiwan include FRESENIUS KABI TAIWAN LTD, FRESENIUS KABI TAIWAN LTD., FRESENIUS KABI TAIWAN LTD., and 4 others. FRESENIUS KABI TAIWAN LTD is the single largest importer with 7 shipments valued at $487.4K USD.

India's carboplatin exports to Taiwan are driven primarily by a handful of large-scale manufacturers. FRESENIUS KABI ONCOLOGY LIMITED with 23 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in Taiwan benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, FRESENIUS KABI ONCOLOGY LIMITED — together account for 100% of total trade value on this route. The average shipment value of $51.7K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as kemocarb carboplatin inj bp 150mg 15ml vial batch no 87230101aa mfg dt 02 2023 exp dt 01 2025 and kemocarb (carboplatin) inj. bp 150mg/15m, suggesting that buyers in Taiwan tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, FRESENIUS KABI TAIWAN LTD is the largest importer with 7 shipments worth $487.4K USD — representing 31% of all carboplatin imports from India on this route. A total of 7 buyers are active on this corridor.